TY - JOUR T1 - Vascular endothelial growth factor in Henoch-Schonlein purpura. JF - The Journal of Rheumatology JO - J Rheumatol SP - 2269 LP - 2273 VL - 28 IS - 10 AU - R Topaloglu AU - A Sungur AU - E Baskin AU - N Besbas AU - U Saatci AU - A Bakkaloglu Y1 - 2001/10/01 UR - http://www.jrheum.org/content/28/10/2269.abstract N2 - OBJECTIVE: To investigate the possible role of vascular endothelial growth factor (VEGF) in the pathogenesis of Henoch-Schonlein purpura (IHSP). METHODS: Plasma VEGF levels were determined in 22 children by ELISA. Ten age matched healthy children served as controls. VEGF expression was evaluated by immunohistochemistry within the cutaneous vasculitic lesion as well as the nonaffected skin and in the skin specimens during the resolution of the disease. RESULTS. Plasma VEGF levels in pg/ml (mean +/- SE) were significantly higher during the acute phase (407.8 +/- 64.92) when compared with the levels seen during the resolution phase (202.17 +/- 26.6; p < 0.002) and in healthy controls (135 +/- 22.8; p < 0.001). Analysis showed that there was a correlation with erythrocyte sedimentation rate. C-reactive protein, white blood cell and platelet count. In all skin specimens, the intensity of the staining of VEGF in the epidermis, dermis, and vascular endothelial bed were evaluated and scored from (+) to (++++). VEGF expression in the epidermis and the vascular bed was more intense in resolving lesions compared with acute vasculitic lesions (p < 0.05). CONCLUSION: Our results suggest that as a potent permeability, chemotactic, and migratory factor, VEGF may play a crucial role in the morphological and functional changes of the vascular bed and inflammatory reaction in HSP. ER -